Aviva Investors and Uttlesford District Council have lodged plans for a new 60,000 sq ft life sciences facility at Chesterford Research Park in Saffron Walden to meet increased demand for space in the Cambridge cluster.
Subject to planning, the three-storey Sidney Sussex Building will be developed on a plot to the east of the park by summer 2024. It will offer individual, flexible suites from 2,226 sq ft to 8,409 sq ft, which can also be combined to facilitate larger requirements.
Julian Cobourne, head of regional offices at Aviva Investors, said: “We believe that extending the facilities at Chesterford Research Park will have a positive impact on the local economy, while also cementing the park’s position as a destination of choice for some of the leading life science businesses globally.”
Current tenants at the park include Arecor, AstraZeneca, Cambridge Epigenetix, Charles River Laboratories, Domainex, Illumina and Lonza.
Aviva and Uttlesford were advised by joint commercial agents Savills and Cheffins, and developer Churchmanor Estates.
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
